Abstract

In this work, the various biological activities of eight organoruthenium(II) complexes were evaluated to reveal correlations with their stability and reactivity in aqueous media. Complexes with general formula [Ru(η6-p-cymene)(X,Y)(Z)] were prepared, where (X,Y) represents either an O,O-ligand (β-diketone), N,O-ligand (8-hydroxyquinoline) or O,S-pyrithione-type ligands (pyrithione = 1-hydroxypyridine-2(1H)-thione) with Cl− or 1,3,5-triaza-7-phosphaadamantane (PTA) as a co-ligand (Z). The tested complexes inhibit the chlamydial growth on HeLa cells, and one of the complexes inhibits the growth of the human herpes simplex virus-2. The chlorido complexes with N,O- and O,S-ligands displayed strong antibacterial activity on Gram-positive strains including the resistant S. aureus (MRSA) and were cytotoxic in adenocarcinoma cell lines. Effect of the structural variation on the biological properties and solution stability was clearly revealed. The decreased bioactivity of the β-diketone complexes can be related to their lower stability in solution. In contrast, the O,S-pyrithione-type complexes are highly stable in solution and the complexation prevents the oxidation of the O,S-ligands. Comparing the binding of PTA and the chlorido co-ligands, it can be concluded that PTA is generally more strongly coordinated to ruthenium, which at the same time decreased the reactivity of complexes with human serum albumin or 1-methylimidazole as well as diminished their bioactivity.

Highlights

  • Ruthenium complexes are prominent subjects in the development of chemotherapeutic agents, and some of them have entered clinical trials

  • AgPF6 /NH4 PF6 to remove the chloride ion and upon the addition of PTA phosphine ligand positively charged complexes were obtained as PF6 − salts

  • Solid state structures 1–3, 5 and 7–8 were characterized by single crystal X-ray crystallography [11,15,16,17,18,20,21,22,23]

Read more

Summary

Introduction

Ruthenium complexes are prominent subjects in the development of chemotherapeutic agents, and some of them have entered clinical trials. Imidazolium trans-[tetrachlorido (dimethylsulfoxide)(1H-imidazole)ruthenate(III)] (NAMI-A) was the first Ru(III) complex introduced into such trials [1], while sodium trans-[tetrachloridobis(1H-indazole)ruthenate (III)] (NKP-1339) is at the moment one of the most investigated non-platinum drugs in clinical development [2]. A novel Ru(II) compound [Ru(4,40 -dimethyl-2,20 -bipyridine)2 -(2(20 ,200 :500 ,2000 -terthiophene)-imidazo-[4,5-f][1,10]-phenanthroline)]Cl2 (TLD-1433) has entered a human clinical trial as a potential nontoxic photodynamic therapeutic agent [3]. Organoruthenium(II) complexes have attracted great interest in chemotherapeutic studies and represent a versatile platform for the design of antitumor metal-containing. The best-known prototypes of half-sandwich Ru(II) complexes are 1,3,5triaza-7-phosphatricyclo-[3.3.1.1]decane (PTA) containing Ru(II)-arene compounds such as [Ru(η6 -p-cymene) (PTA)Cl their significant antimetastatic properties 2 ] (RAPTA-C).

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call